AML Rapid Mutation Panel
Use
This panel interrogates 7 genes (FLT3, IDH1/IDH2, CEBPA, KIT, NPM1, TP53) for clinically significant mutations associated with treatment selection and/or prognosis in acute myeloid leukemia (AML). FLT3 mutations (ITDs and TKD) correlate with poor outcomes but may qualify patients for FDA‑approved targeted therapy (midostaurin). Gain‑of‑function mutations in IDH1/IDH2 are frequent in AML and associated with unfavorable prognosis; IDH inhibitors are FDA‑approved for mutated AML. CEBPA biallelic mutations suggest improved outcomes; KIT mutations indicate poorer prognosis in CBF‑AML; NPM1 mutations may predict favorable response; TP53 mutations indicate poor outcomes and complex karyotypes.
Special Instructions
Not provided.
Limitations
Analytical sensitivity varies: FLT3 by PCR/fragment analysis detects to ~5% mutant allele fraction; IDH1/IDH2 by Sanger sequencing detects to ~20%; NGS for CEBPA, KIT, NPM1, TP53 detects SNVs and indels to ~5%, per AMP/ACMG, benign variants are not reported.
Methodology
NGS
Biomarkers
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
3 mL
Container
EDTA tube (lavender‑top)
Other tests from different labs that may be relevant